TNXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Tonix Pharmaceuticals Holding Corp.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$5.73−0.31 (-5.13%)
Close on Oct 19, 2026
- Market cap
- $95.32M
- P/E (TTM)
- –
- Dividend yield
- –
Tonix Pharmaceuticals Holding Corp. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q4 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zembrace Symtouch [Member] | $10.64M | $10.22M | $9.31M | $8.67M | $8.57M | $8.73M | $8.55M | $9.07M | $9.88M | $6.30M | 36.6% | +24.2% |
| Tosymra [Member] | $2.35M | $2.19M | $2.37M | $1.63M | $1.26M | $1.32M | $1.55M | $2.22M | $2.58M | $1.46M | 8.1% | +86.2% |
By region
From the segment and revenue-disaggregation notes of Tonix Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.